These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 3586432)

  • 1. [Surgical treatment following administration of prostaglandin E in a ductus-dependent neonate with cyanotic congenital heart disease].
    Tashiro T; Todo K; Yanai T; Haruta Y; Eto Y; Hashimoto T; Kosuga K; Kato H
    Kyobu Geka; 1987 Mar; 40(4):271-9. PubMed ID: 3586432
    [No Abstract]   [Full Text] [Related]  

  • 2. Modified Blalock-Taussig shunt following long-term administration of prostaglandin E1 for ductus-dependent neonates with cyanotic congenital heart disease.
    Yokota M; Muraoka R; Aoshima M; Nomoto S; Shiraishi Y; Kyoku I; Kitano M; Shimada I; Nakano H; Ueda K
    J Thorac Cardiovasc Surg; 1985 Sep; 90(3):399-403. PubMed ID: 4033176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Long-term treatment using prostaglandin E2 in congenital heart defects with the pulmonary circulation being supplied by a patent ductus arteriosus].
    Hruda J; Samánek M; First T; Vorísková M; Skovránek J
    Cesk Pediatr; 1985 May; 40(5):257-62. PubMed ID: 3860302
    [No Abstract]   [Full Text] [Related]  

  • 4. Oral administration of prostaglandin E2 in the hypoplastic left heart syndrome.
    Fujiseki Y; Yamamoto H; Hattori M; Yamawaki Y; Goto M; Shimada M
    Jpn Heart J; 1983 May; 24(3):481-7. PubMed ID: 6576179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proceedings: Emergency treatment of certain cyanotic heart defects with prostaglandin E2.
    Olley PM; Coceani F
    Br Heart J; 1976 Aug; 38(8):877. PubMed ID: 973917
    [No Abstract]   [Full Text] [Related]  

  • 6. Prostaglandin treatment of newborns with ductal-dependent congenital heart disease.
    Linday LA; Engle MA
    Pediatr Ann; 1981 Apr; 10(4):29-38. PubMed ID: 7232040
    [No Abstract]   [Full Text] [Related]  

  • 7. [Prostaglandin E1: effect on blood gases in infants with cyanotic congenital heart disease (author's transl)].
    Schöber JG; Kellner M; Christian I
    Klin Padiatr; 1977 Sep; 189(5):365-9. PubMed ID: 21323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostaglandin E1 in the neonate with heart disease.
    Schleman MM; Casta A; Mongkolsmai C; Black IF
    Adv Prostaglandin Thromboxane Res; 1980; 7():879-81. PubMed ID: 7369051
    [No Abstract]   [Full Text] [Related]  

  • 9. Editorial: Nonsurgical palliation of congenital heart malformations.
    Olley PM
    N Engl J Med; 1975 Jun; 292(24):1292-4. PubMed ID: 48193
    [No Abstract]   [Full Text] [Related]  

  • 10. [Use of prostaglandin E1 in ductus-dependent congenital cardiopathies].
    Marcial MB; Maluf M; Atik E; Vargas H; Baucia JA; Verginelli G
    Arq Bras Cardiol; 1983 Jun; 40(6):383-6. PubMed ID: 6686760
    [No Abstract]   [Full Text] [Related]  

  • 11. [Palliative operation for congenital heart disease with increased pulmonary blood flow during neonates and infancy].
    Shimada M; Tsunemoto M; Ota Y; Sasaki T; Masaki H; Hojo H; Naganuma M; Koike K; Takano Y
    Kyobu Geka; 1984 Feb; 37(2):148-53. PubMed ID: 6201641
    [No Abstract]   [Full Text] [Related]  

  • 12. Cardiovascular therapy in the newborn.
    Sandor GG
    Clin Invest Med; 1985; 8(4):360-7. PubMed ID: 3907921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of prostaglandin E1 and E2 in the management of neonatal heart disease.
    Olley PM; Coceani F; Rowe RD
    Adv Prostaglandin Thromboxane Res; 1978; 4():345-53. PubMed ID: 645511
    [No Abstract]   [Full Text] [Related]  

  • 14. [Prolonged prostaglandin E-1 therapy of newborn infants with congenital heart defects].
    Kertész E; Hencz P; Tekulics P; Beviz J; Száva J; Matkó I; Kovács G
    Orv Hetil; 1980 May; 121(20):1197-9. PubMed ID: 7413203
    [No Abstract]   [Full Text] [Related]  

  • 15. Patent ductus arteriosus in the premature neonate.
    Page GG
    Heart Lung; 1985 Mar; 14(2):156-62. PubMed ID: 3882636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. E-type prostaglandins: a new emergency therapy for certain cyanotic congenital heart malformations.
    Olley PM; Coceani F; Bodach E
    Circulation; 1976 Apr; 53(4):728-31. PubMed ID: 56243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Value of prostaglandin E1 in cardiac malformations in the newborn infant].
    Sassolas F; Bozio A; Andre M; Jocteur-Monrozier D; Champsaur G; Normand J
    Pediatrie; 1984 Jun; 39(4):245-52. PubMed ID: 6504667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary artery growth during treatment with oral prostaglandin E2 in ductus dependent cyanotic congenital heart disease.
    MacMahon P; Gorham PF; Arnold R; Wilkinson JL; Hamilton DI
    Arch Dis Child; 1983 Mar; 58(3):187-9. PubMed ID: 6573159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The transition from fetal to neonatal circulation: normal responses and implications for infants with heart disease.
    Friedman AH; Fahey JT
    Semin Perinatol; 1993 Apr; 17(2):106-21. PubMed ID: 8327901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prostaglandin treatment of ductus-dependent congenital heart defects].
    Olsson B; Björkhem G; Lundström NR
    Lakartidningen; 1984 Oct; 81(40):3619-22. PubMed ID: 6541738
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.